These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Patel GV; Patel VB; Pathak A; Rajput SJ Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843 [TBL] [Abstract][Full Text] [Related]
6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464 [TBL] [Abstract][Full Text] [Related]
7. Dual strategy to improve the oral bioavailability of efavirenz employing nanomicelles and curcumin as a bio-enhancer. Fuentes P; Bernabeu E; Bertera F; Garces M; Oppezzo J; Zubillaga M; Evelson P; Jimena Salgueiro M; Moretton MA; Höcht C; Chiappetta DA Int J Pharm; 2024 Feb; 651():123734. PubMed ID: 38142017 [TBL] [Abstract][Full Text] [Related]
8. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®. Honório Tda S; Pinto EC; Rocha HV; Esteves VS; dos Santos TC; Castro HC; Rodrigues CR; de Sousa VP; Cabral LM AAPS PharmSciTech; 2013 Sep; 14(3):1244-54. PubMed ID: 23943401 [TBL] [Abstract][Full Text] [Related]
9. Study the influence of formulation process parameters on solubility and dissolution enhancement of efavirenz solid solutions prepared by hot-melt extrusion: a QbD methodology. Pawar J; Suryawanshi D; Moravkar K; Aware R; Shetty V; Maniruzzaman M; Amin P Drug Deliv Transl Res; 2018 Dec; 8(6):1644-1657. PubMed ID: 29426975 [TBL] [Abstract][Full Text] [Related]
10. Polymeric Precipitation Inhibitor Assisted Supersaturable SMEDDS of Efavirenz Based on Experimental Observations and Molecular Mechanics. Singh M; Singh D; Mahajan S; Sheikh BA; Bedi N Curr Drug Deliv; 2021; 18(4):513-530. PubMed ID: 32735521 [TBL] [Abstract][Full Text] [Related]
11. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Xia D; Cui F; Piao H; Cun D; Piao H; Jiang Y; Ouyang M; Quan P Pharm Res; 2010 Sep; 27(9):1965-76. PubMed ID: 20585842 [TBL] [Abstract][Full Text] [Related]
12. Efavirenz Dissolution Enhancement IV-Antisolvent Nanocrystallization by Sonication, Physical Stability, and Dissolution. Sartori GJ; Prado LD; Rocha HVA AAPS PharmSciTech; 2017 Nov; 18(8):3011-3020. PubMed ID: 28493004 [TBL] [Abstract][Full Text] [Related]
13. Efficiency of single pharmaceutical surfactants to mimic intestinal biorelevant media solubilization and dissolution of etravirine: Comparison of intrinsic and film dissolution models. Oktay AN; Polli JE Eur J Pharm Sci; 2024 May; 196():106746. PubMed ID: 38499112 [TBL] [Abstract][Full Text] [Related]
14. Concentration and composition dependent aggregation of Pluronic- and Poly-(2-oxazolin)-Efavirenz formulations in biorelevant media. Endres S; Karaev E; Hanio S; Schlauersbach J; Kraft C; Rasmussen T; Luxenhofer R; Böttcher B; Meinel L; Pöppler AC J Colloid Interface Sci; 2022 Jan; 606(Pt 2):1179-1192. PubMed ID: 34487937 [TBL] [Abstract][Full Text] [Related]
15. Solubility and dissolution performances of spray-dried solid dispersion of Efavirenz in Soluplus. Lavra ZM; Pereira de Santana D; Ré MI Drug Dev Ind Pharm; 2017 Jan; 43(1):42-54. PubMed ID: 27349377 [TBL] [Abstract][Full Text] [Related]
16. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz. Avachat AM; Parpani SS Colloids Surf B Biointerfaces; 2015 Feb; 126():87-97. PubMed ID: 25543986 [TBL] [Abstract][Full Text] [Related]
17. Identification of the in vivo relevant dissolution media for the three active components in EGb 761 tablet for better correlation with their pharmacokinetics in healthy subjects. Zhao J; Cheng SW; Ng WL; Zhang Y; Shek TL; Ren T; Yan X; Li K; Wang J; Zuo Z Eur J Pharm Sci; 2020 Nov; 154():105515. PubMed ID: 32798718 [TBL] [Abstract][Full Text] [Related]
18. Effect of High-Energy Milling on the Dissolution of Anti-HIV Drug Efavirenz in Different Solvents. Ataollahi N; Broseghini M; Ferreira FF; Susana A; Pizzato M; Scardi P ACS Omega; 2021 May; 6(19):12647-12659. PubMed ID: 34056416 [TBL] [Abstract][Full Text] [Related]
19. Lipid based delivery of Efavirenz: An answer to its erratic absorption and food effect. Kamboj S; Sethi S; Rana V Eur J Pharm Sci; 2018 Oct; 123():199-216. PubMed ID: 30031861 [TBL] [Abstract][Full Text] [Related]
20. Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study. Varshosaz J; Taymouri S; Jahanian-Najafabadi A; Alizadeh A IET Nanobiotechnol; 2018 Sep; 12(6):795-806. PubMed ID: 30104454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]